Completed PHASE4 INTERVENTIONAL NCT00147511

Time To Efficacy and Onset Of Action Of Linezolid

Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections

Sponsor: Pfizer

Conditions Gram-Positive Bacterial Infections Skin and Connective Tissue Diseases

Interventions linezolid

Updated 5 times since 2017 Last updated: May 9, 2011 Started: Jun 30, 2003 Completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Gram-Positive Bacterial Infections and Skin and Connective Tissue Diseases, this trial is completed. The trial is conducted by Pfizer and has accumulated 5 data snapshots since 2003. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.